TY - JOUR
T1 - PsychDT working group
T2 - Report psychosocial aspects of artificial pancreas systems
AU - Barnard, Katharine D.
AU - Venkat, Manu V.
AU - Close, Kelly
AU - Heinemann, Lutz
AU - Weissberg-Benchell, Jill
AU - Hood, Korey K.
AU - Kubiak, Thomas
AU - Kowalski, Aaron J.
AU - Laffel, Lori
N1 - Funding Information:
1Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK 2Close Concerns, San Francisco, CA, USA 3The diaTribe Foundation, San Francisco, CA, USA 4Science & Co, Dusseldorf, Germany 5Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA 6Pediatrics, Psychiatry and Behavioural Sciences, Stanford University School of Medicine, San Francisco, CA, USA 7Health Psychology, Johannes Gutenberg University, Mainz, Germany 8Juvenile Diabetes Research Foundation Ltd, New York, NY, USA 9Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Leona and Harry Helmsley Charitable Trust funded the Artificial Pancreas Psychosocial measures project that is associated with, but not directly responsible for, this working group.
PY - 2015/7
Y1 - 2015/7
N2 - Background: Diabetes technology is a cornerstone of diabetes management in the 21st century, with advances in available devices over recent years playing a central role in the way that health care has progressed. Psychosocial interventions have been shown to have a positive impact on glycemic control, reduce psychological distress and reduce costs of health care. Addressing and improving psychosocial outcomes that complement biomedical improvements and looking to the future are crucial to enhance patient acceptance of artificial pancreas (AP) systems. Methods: To achieve closer collaboration and comparability across different AP research trials, a working group was established. Results: Existing measures fail to adequately capture the extent to which human and psychological factors play a role in the uptake and efficient use of AP systems. Understanding these factors will ultimately lead to the most benefit for users. Reliable measures of the psychosocial impact of AP systems for users is crucial to ensure that (1) regulatory authorities are able to robustly consider these aspects as part of their approval process, (2) government and private payers are able to factor these aspects into their decisions regarding reimbursement, and (3) persons with diabetes maximize benefits in terms of both glycemic control and quality of life to minimize the burden of diabetes in everyday life. Conclusions: This working group will serve as a platform to foster exchange, identify research needs, and guide and initiate collaborative research laying the groundwork for optimal utilization of diabetes technology in clinical diabetes care. A close collaboration among all key stakeholders is crucial to ensure that devices are designed, trialed, approved, and provided with minimal user burden and maximum beneficial effect.
AB - Background: Diabetes technology is a cornerstone of diabetes management in the 21st century, with advances in available devices over recent years playing a central role in the way that health care has progressed. Psychosocial interventions have been shown to have a positive impact on glycemic control, reduce psychological distress and reduce costs of health care. Addressing and improving psychosocial outcomes that complement biomedical improvements and looking to the future are crucial to enhance patient acceptance of artificial pancreas (AP) systems. Methods: To achieve closer collaboration and comparability across different AP research trials, a working group was established. Results: Existing measures fail to adequately capture the extent to which human and psychological factors play a role in the uptake and efficient use of AP systems. Understanding these factors will ultimately lead to the most benefit for users. Reliable measures of the psychosocial impact of AP systems for users is crucial to ensure that (1) regulatory authorities are able to robustly consider these aspects as part of their approval process, (2) government and private payers are able to factor these aspects into their decisions regarding reimbursement, and (3) persons with diabetes maximize benefits in terms of both glycemic control and quality of life to minimize the burden of diabetes in everyday life. Conclusions: This working group will serve as a platform to foster exchange, identify research needs, and guide and initiate collaborative research laying the groundwork for optimal utilization of diabetes technology in clinical diabetes care. A close collaboration among all key stakeholders is crucial to ensure that devices are designed, trialed, approved, and provided with minimal user burden and maximum beneficial effect.
KW - Artificial pancreas
KW - Diabetes technologies
KW - Human factors
KW - Psychosocial
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85018194277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018194277&partnerID=8YFLogxK
U2 - 10.1177/1932296815588332
DO - 10.1177/1932296815588332
M3 - Article
C2 - 26085567
AN - SCOPUS:85018194277
VL - 9
SP - 925
EP - 928
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
IS - 4
ER -